As of late April 2026, the consensus among financial analysts for leans toward a Hold , though it remains a polarizing "value" play with significant long-term upside potential. The "Buy" Case: Long-Term Growth & Valuation
Management has reaffirmed its 2026 outlook, expecting core EPS growth of 7% to 9%. Key growth drivers include Arexvy (RSV vaccine) and expansion into specialty medicines like HIV and Oncology. gsk buy or sell
Despite strong fundamentals, many analysts recommend caution in the immediate term: GSK (GSK) Earnings Expected to Grow: Should You Buy? As of late April 2026, the consensus among
Several valuation models suggest the stock is significantly undervalued. Discounted Cash Flow (DCF) analyses from Yahoo Finance estimate the stock is trading at a ~52-53% discount to its fair value. As of late April 2026